<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563235</url>
  </required_header>
  <id_info>
    <org_study_id>2018R1035-4</org_study_id>
    <nct_id>NCT03563235</nct_id>
  </id_info>
  <brief_title>Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules</brief_title>
  <acronym>CSOPOPWXJG</acronym>
  <official_title>Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Academy of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Academy of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis is a common senile disease with a high incidence. The Chinese medicine
      differentiation treatment has small side effects and can be taken for a long time, which has
      certain advantages. This project adopts the experience of the person in charge of the
      project-Xulin Jiangu Granules and clinically collects patients with postmenopausal
      osteoporosis (kidney deficiency and blood stasis syndrome).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized control method was used to observe the clinical efficacy of the treatment of
      postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome) with jiujian jiangu
      granules, combined with the gene expression of bone metabolism markers BALP, PINP, TRACP and
      S-CTX, and RANK, RANKL and OPG Detection, compared with the control group of ossification
      trihydrate capsules, to explore the mechanism of the treatment of postmenopausal osteoporosis
      by the continued Xulin Jiangu granules, and lay the foundation for the development of new
      drugs.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone density（BMD）</measure>
    <time_frame>Xulin Jiangu treats for up to six months</time_frame>
    <description>BMD is the gold standard of oeteoporosis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postmenopausal Osteoporoses</condition>
  <arm_group>
    <arm_group_label>Xulin Jiangu granules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xulin Jiangu granules</intervention_name>
    <description>Xulin Jiangu granules tablets</description>
    <arm_group_label>Calcitriol capsules</arm_group_label>
    <arm_group_label>Xulin Jiangu granules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol capsules</intervention_name>
    <description>Calcitriol capsules tablets</description>
    <arm_group_label>Calcitriol capsules</arm_group_label>
    <arm_group_label>Xulin Jiangu granules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 2 years prior and met the diagnostic criteria for osteoporosis according to
             the &quot;clinical practice guidelines of traditional medicine for primary osteoporosis

          -  met the CM diagnostic criteria according to &quot;Syndrome Differentiation in Modern
             Research of Traditional Chinese Medicine

        Exclusion Criteria:

          -  patients who did not meet the diagnostic criteria for osteoporosis or CM standards

          -  patients with rheumatoid arthritis, diabetes, secondary osteoporosis due to
             hyperthyroidism, and severe cardiovascular or cerebrovascular diseases

          -  patients with abnormal liver and/or Shen function test results

          -  patients with osteoporosis who had received treatment with CM within the last month,
             hormone replacement therapy and calcitonin within the past three months, or
             bisphosphonates for 15 consecutive days within the past 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fujian Academy of Trational Chiness Medicine</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>kidney deficiency and blood stasis syndrome</keyword>
  <keyword>Xuling Jiangu Granules</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Blind Loop Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

